


~~Please add new Claim 20 as follows:~~

~~CM-20.~~ A dibenz[b,e]oxepin compound in cis form
having the formula ~~8 c~~



and pharmaceutically acceptable salts thereof.

REMARKS

Claims 2, 18 and 20 are pending, with Claim 20 being the sole independent claim. Claims 1, 3-10, 13-17, and 19 are cancelled without prejudice or disclaimer of the subject matter recited therein. Claim 20 has been added to specifically recite the formula of cis-11-(3-dimethylamino-propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid as discussed at specification page 22 (compound 20). Methods for producing this compound may be found, for instance, in Examples 4 and 35. Claims 2 and 18 have been amended solely to depend from Claim 20. The Examiner will, accordingly, appreciate both that the claims as presented are fully enabled and that no new matter has been added.

Claims 1-10 and 13-19 stand rejected under 35 U.S.C. § 102(g) as being anticipated, or in the alternative, under 35 U.S.C. § 103 as being obvious over Lever, et al. U.S. Patent Nos. 4,871,865 (of record) and